OPINION Therapeutic targets to reduce cardiovascular disease in type 2 diabetes

被引：0
作者：
DeSouza, Cyrus [2 ,3 ]
Fonseca, Vivian [1 ]
机构：
[1] Tulane Univ, Hlth Sci Ctr, 1430 Tulane Ave,SL 53, New Orleans, LA 70118 USA
[2] Univ Nebraska Med Ctr, Omaha, NE USA
[3] Omaha Vet Affairs Med Ctr, Omaha, NE USA
来源：
NATURE REVIEWS DRUG DISCOVERY | 2009年 / 8卷 / 05期
关键词：
GLUCAGON-LIKE PEPTIDE-1; CYCLASE-ACTIVATING POLYPEPTIDE; NA+-GLUCOSE COTRANSPORTER; CORONARY-ARTERY-DISEASE; FACTOR-KAPPA-B; ENDOCANNABINOID SYSTEM; INTESTINAL POLYPEPTIDE; MYOCARDIAL-INFARCTION; ENDOTHELIAL FUNCTION; EMERGING ROLES;
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The potential cardiovascular risks that are associated with drugs for type 2 diabetes have recently raised considerable clinical and regulatory concerns. As some risk factors for cardiovascular disease and type 2 diabetes are related, identifying agents that target shared underlying pathways and processes is an attractive therapeutic strategy. In this article, we review the background to and the implications of recent regulatory guidance on the development of new drugs for diabetes, and discuss the potential cardiovascular effects of selected classes of diabetes drugs that are currently being investigated.
引用
收藏
页码：361 / 367
页数：7
相关论文
共 70 条
  • [61] Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages
    Sugamura, Koichi
    Sugiyama, Seigo
    Nozaki, Toshimitsu
    Matsuzawa, Yasushi
    Izumiya, Yasuhiro
    Miyata, Keishi
    Nakayama, Masafumi
    Kaikita, Koichi
    Obata, Toru
    Takeya, Motohiro
    Ogawa, Hisao
    [J]. CIRCULATION, 2009, 119 (01) : 28 - U63
  • [62] Inflammatory mechanisms in the regulation of insulin resistance
    Tilg, Herbert
    Moschen, Alexander R.
    [J]. MOLECULAR MEDICINE, 2008, 14 (3-4) : 222 - 231
  • [63] Tousoulis D, 2008, POSTGRAD MED J, V84, P368, DOI 10.1136/hrt.2005.066936
  • [64] Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
    Turner, RC
    Holman, RR
    Stratton, IM
    Cull, CA
    Matthews, DR
    Manley, SE
    Frighi, V
    Wright, D
    Neil, A
    Kohner, E
    McElroy, H
    Fox, C
    Hadden, D
    [J]. LANCET, 1998, 352 (9131) : 854 - 865
  • [65] A Functional Role for Sodium-Dependent Glucose Transport across the Blood-Brain Barrier during Oxygen Glucose Deprivation
    Vemula, Sharanya
    Roder, Karen E.
    Yang, Tianzhi
    Bhat, G. Jayarama
    Thekkumkara, Thomas J.
    Abbruscato, Thomas J.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 328 (02) : 487 - 495
  • [66] Viveros M. P., 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P220, DOI 10.2174/187153008785700082
  • [67] G-protein-coupled receptors and islet function - Implications for treatment of type 2 diabetes
    Winzell, Maria Sorhede
    Ahren, Bo
    [J]. PHARMACOLOGY & THERAPEUTICS, 2007, 116 (03) : 437 - 448
  • [68] SIRT1 Exerts Anti-Inflammatory Effects and Improves Insulin Sensitivity in Adipocytes
    Yoshizaki, Takeshi
    Milne, Jill C.
    Imamura, Takeshi
    Schenk, Simon
    Sonoda, Noriyuki
    Babendure, Jennie L.
    Lu, Juu-Chin
    Smith, Jesse J.
    Jirousek, Michael R.
    Olefsky, Jerrold M.
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2009, 29 (05) : 1363 - 1374
  • [69] Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice
    Zhang, Qing-jun
    Wang, Zhao
    Chen, Hou-Zao
    Zhou, Shuang
    Zheng, Wei
    Liu, Guang
    Wei, Yu-sheng
    Cai, Hua
    Liu, De-pei
    Liang, Chih-chuan
    [J]. CARDIOVASCULAR RESEARCH, 2008, 80 (02) : 191 - 199
  • [70] Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)
    Zhou, LB
    Cryan, EV
    D'Andrea, MR
    Belkowski, S
    Conway, BR
    Demarest, KT
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 90 (02) : 339 - 346
1234567